Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ark Biosciences of Shanghai In-Licenses RSV Treatment from Roche

publication date: Jun 19, 2014
Ark Biosciences, an innovative Shanghai biotech startup, has in-licensed rights to Roche's Respiratory Syncytial Virus (RSV) drug candidate, AK0529. Pre-clinical work on AK0529 has been completed. Ark will receive all of Roche’s data documentation for the drug along with its API. Roche will receive an upfront payment, milestones and royalties. Ark, which will manufacture the product, owns global rights to AK0529, including the right to sub-license. More details....

Stock Symbol: (VX: ROG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital